These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30148444)

  • 1. Growth and body mass index in a cohort of patients with juvenile idiopathic arthritis: effects of second line treatments.
    Marino A; Stagi S; Simonini G; Carli N; Caparello MC; Giani T; Pagnini I; De Masi S; Cimaz R
    Clin Exp Rheumatol; 2018; 36(5):929-933. PubMed ID: 30148444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of biologic treatments on growth in children with juvenile idiopathic arthritis.
    Uettwiller F; Perlbarg J; Pinto G; Bader-Meunier B; Mouy R; Compeyrot-Lacassagne S; Melki I; Wouters C; Prieur AM; Landais P; Polak M; Quartier P
    J Rheumatol; 2014 Jan; 41(1):128-35. PubMed ID: 24293576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study on 158 Thai patients with juvenile idiopathic arthritis followed in a single center over a 15-year period.
    Vilaiyuk S; Soponkanaporn S; Jaovisidha S; Benjaponpitak S; Manuyakorn W
    Int J Rheum Dis; 2016 Dec; 19(12):1342-1350. PubMed ID: 26176300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian reserve in children with juvenile idiopathic arthritis using biologic disease-modifying anti-rheumatic drugs.
    Ozer Y; Yildiz M; Turan H; Tarcin G; Bingol Aydin D; Gunalp A; Haslak F; Kilic Konte E; Aslan E; Koker O; Bayramoglu E; Sahin S; Adrovic A; Barut K; Kasapcopur O; Evliyaoglu O
    Clin Rheumatol; 2024 Jan; 43(1):399-406. PubMed ID: 37646858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
    Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
    Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
    Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
    Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.
    Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T;
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
    Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
    Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
    Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
    Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.
    Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL
    Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parents' willingness to pay for biologic treatments in juvenile idiopathic arthritis.
    Burnett HF; Ungar WJ; Regier DA; Feldman BM; Miller FA
    Value Health; 2014 Dec; 17(8):830-7. PubMed ID: 25498778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies.
    Vidqvist KL; Malin M; Varjolahti-Lehtinen T; Korpela MM
    Rheumatology (Oxford); 2013 Nov; 52(11):1999-2003. PubMed ID: 23893666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.
    Klotsche J; Raab A; Niewerth M; Sengler C; Ganser G; Kallinich T; Niehues T; Hufnagel M; Thon A; Hospach T; Horneff G; Minden K
    Arthritis Rheumatol; 2016 Dec; 68(12):3023-3034. PubMed ID: 27332999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
    Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M;
    Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Juvenile idiopathic arthritis managed in the new millennium: one year outcomes of an inception cohort of Australian children.
    Tiller G; Buckle J; Allen R; Munro J; Gowdie P; Cox A; Akikusa J
    Pediatr Rheumatol Online J; 2018 Nov; 16(1):69. PubMed ID: 30413164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.